Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative

• Published in: Neuro-degenerative diseases Vol. 18; no. 4; p. 173
• Main Authors: Iddi, Samuel, Li, Dan, Aisen, Paul S, Rafii, Michael S, Litvan, Irene, Thompson, Wesley K, Donohue, Michael C
• Format: Journal Article
• Language: English
• Published: Switzerland 01.01.2018
• Subjects: Adult; Aged; Aged, 80 and over; Autopsy - methods; Biomarkers - analysis; Biomarkers - cerebrospinal fluid; Corpus Striatum - metabolism; Disease Progression; Female; Gray Matter - metabolism; Humans; Male; Middle Aged; Parkinson Disease - cerebrospinal fluid; Parkinson Disease - diagnosis; Parkinson Disease - metabolism; Parkinsonian Disorders - cerebrospinal fluid; Parkinsonian Disorders - diagnosis; Parkinsonian Disorders - metabolism; Multilevel Bayesian models; Latent time shift; Joint mixed-effects models; Biomarkers; Clinical diagnosis; Disease trajectories; Multicohort longitudinal data; Parkinson’s disease

Parkinson's disease is the second most common neurological disease and affects about 1% of persons over the age of 60 years. Due to the lack of approved surrogate markers, confirmation of the disease still requires postmortem examination. Identifying and validating biomarkers are essential step...